New study tracks Mylotarg's safety in korean AML patients
NCT ID NCT05189639
First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 17 times
Summary
This study watches adults in Korea with newly diagnosed acute myeloid leukemia (AML) who are receiving the drug Mylotarg. Researchers will track side effects and how the disease responds to treatment. The goal is to better understand the drug's safety and effectiveness in real-world hospital settings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul national university hospital
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.